Company Information
Industry 制造业
Company Introduction 山东科源制药股份有限公司是国家高新技术企业、力诺集团健康产业核心成员企业、山东省化学合成药物骨干企业,致力于化学原料药产品研发、生产与销售以及国际高端CMO/CDMO业务的开发,与国际多家知名企业建立了战略合作伙伴关系。 公司目前已经获得国内GMP证书、欧盟CEP证书,通过了美国FDA、加拿大、日本、韩国等国际官方认证。 主要产品有盐酸二甲双胍、格列齐特、单硝酸异山梨酯、硝酸异山梨酯、盐酸罗哌卡因、乳糖酸克拉霉素、兰索拉唑、甲钴胺等,逐渐形成了降糖类、心血管类、麻醉剂类、抗肿瘤类、精神类等五大类药物并举的产品格局,为公司未来发展注入新的活力。 公司拥有较为完善的生产、研发体系。生产厂区位于济南市商河县开发区,占地200余亩。公司研发拥有省级认定企业技术中心、市级博士后创新实践基地,拥有一支专业型、国际化的研发团队。 “致力于成为优秀的化药制造商”,科源制药始终秉承力诺集团“产业报国,追求卓越”的企业使命,在保持公司传统产品稳定增长的同时,大力发展CMO/CDMO业务,着力推进特色原料的产业布局,将科源制药打造成为国内一流、国际有影响力的公司,为人类健康事业做出更大贡献。
Main Business 化学原料药及其制剂产品的研发、生产和销售。
Legal Representative 蒋红升
Top Executives
董事长:蒋红升
副董事长:邹晓虹
董事:邹晓虹,武滨,李建文,蒋红升
独立董事:袁康,葛永波,郑海英
Top 5 Shareholder
Shareholder name Nature Holding Date
力诺投资控股集团有限公司限售股34.39%30/06/2024
问泽鸿流通A股7.76%30/06/2024
济南安富创业投资合伙企业(有限合伙)限售股5.82%30/06/2024
济南市财金科技投资有限公司流通A股4.72%30/06/2024
济南鼎佑健康产业投资合伙企业(有限合伙)流通A股3.88%30/06/2024
Company Secretary 李春桦
Solicitors 北京德恒律师事务所
Auditors 信永中和会计师事务所(特殊普通合伙)
Tel No 0531-88729558
Fax No 0531-84779766
Website www.keyuanpharm.com
Email keyuanzhiyao@keyuanpharm.com;lich@linuo.com;changgy@linuo.com
Company Address
Register: 山东济南市山东商河经济开发区科源街
Office: 山东济南市山东商河经济开发区科源街
Listing Date 04/04/2023
Shares Capital
Shares Capital: 108,290,000
Total A Share: 108,290,000
Listed A Share: 62,552,000
Non-tradable A Share: 45,738,000
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.760
DPS(RMB)* ¥ 0.300
NBV Per Share(RMB)* ¥ 12.290
Market Capitalization(RMB) 1.185B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.